Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Hyaluronic Acid,HYDROXYPROPYLMETHYLCELLULOSE
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Allergan Aesthetics looks to further develop the Hybrid Injectables category by introducing its first dual-effect product, which combines the two active ingredients - hyaluronic acid, a well-known ingredient found in facial fillers and calcium hydroxyapa...
Product Name : Juvederm Volux XC
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 29, 2022
Lead Product(s) : Hyaluronic Acid,HYDROXYPROPYLMETHYLCELLULOSE
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : Alcon Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Immediate Effects of Lipid-Based and Non-Lipid Artificial Tears on Corneal Aberrations
Details : HYDROXYPROPYLMETHYLCELLULOSE is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Carbohydrate
Upfront Cash : Inapplicable
January 20, 2025
Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : Alcon Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE,Dextrans,Glycerine
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : OcuMension Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
OcuMension Acquires Alcon Eye Drops with 16.7% Equity, Strategic Partnership Begins
Details : OcuMension will acquire outright, Tears Natural Forte, Bion Tears, Alcaine, Fluorescite, and Cyclogyl, in the Chinese market and AR-15512, a novel topical drug candidate for dry eye.
Product Name : Tears Naturale Forte
Product Type : Carbohydrate
Upfront Cash : Undisclosed
August 12, 2024
Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE,Dextrans,Glycerine
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : OcuMension Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Merz Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Effects of Calcium Hydroxylapatite on Cellulite Dimples in the Buttocks
Details : Calcium Hydroxyapatite is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Cellulite.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 01, 2023
Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Merz Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : Merz Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Xeomin, Radiesse, and Belotero Facial/Neck Rejuvenational
Details : Calcium Hydroxylapatite is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 10, 2021
Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : Merz Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hyaluronic Acid,HYDROXYPROPYLMETHYLCELLULOSE
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Innovative Luminera
Deal Size : Undisclosed
Deal Type : Acquisition
Allergan Aesthetics, an AbbVie Company, Acquires Innovative Luminera Dermal Filler Business
Details : Allergan Aesthetics will acquire Luminera's full dermal filler portfolio and R&D pipeline further enhancing Allergan Aesthetics' leading dermal filler portfolio with its JUVÉDERM® collection of fillers.
Product Name : HArmonyCa
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 07, 2020
Lead Product(s) : Hyaluronic Acid,HYDROXYPROPYLMETHYLCELLULOSE
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Innovative Luminera
Deal Size : Undisclosed
Deal Type : Acquisition